What determines the later clinical course of patients who do not undergo colectomy at the first attack? a Japanese cohort study on ulcerative colitis

Digestion

Volumn 81, Issue 2, 2010, Pages 104-112

  Shiga, Hisashi ^a   Takagi, Sho ^a   Inoue, Ryusuke ^b,c   Kinouchi, Yoshitaka ^a   Ohkubo, Takayoshi ^a,c   Takahashi, Seiichi ^a   Negoro, Kenichi ^a   Yokoyama, Hiroshi ^a   Kato, Seiichi ^a   Fukushima, Kouhei ^d   Hiwatashi, Nobuo ^e   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d Department of Surgery   (Japan)

^e Iwaki Kyoritsu General Hospital   (Japan)

Author keywords

Colectomy; Hazard ratio; Relapse, ulcerative colitis; Ulcerative colitis, prognosis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CYCLOSPORIN; HEMOGLOBIN; MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; COHORT ANALYSIS; COLON RESECTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROCTITIS; PROPORTIONAL HAZARDS MODEL; RELAPSE; RISK FACTOR; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CHILD; COHORT STUDIES; COLECTOMY; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 73649136536     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229773     Document Type: Article

References (29)

1. Gelbmann CM: Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease - do we have reliable markers? Inflamm Bowel Dis 2000; 6: 123-131
2. Chakravarty BJ: Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993; 88: 852-855
3. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, Satsangi J: Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-1087
4. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP: Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910
5. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjödahl RI: Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-835
6. Oshitani N, Kitano A, Fukushima R, Okabe H, Kashima K, Nakamura S, Obata A, Matsumoto T, Okawa K, Kobayashi K: Predictive factors for the response of ulcerative colitis patients during the acute-phase treatment. Digestion 1990; 46: 107-113
7. Leijonmarck CE, Persson PG, Hellers G: Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 1990; 31: 329-333
8. Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, Tsianos E, Beltrami M, Odes S, Munkholm P, Vatn M, Stockbrugger RW, Moum B: Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007; 132: 507-515
9. Hiwatashi N, Yamazaki H, Kimura M, Morimoto T, Watanabe H, Toyota T: Clinical course and long-term prognosis of Japanese patients with ulcerative colitis. Gastroenterol Jpn 1991; 26: 312-318
10. Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170(suppl):2-6; discussion 16-19
11. Truelove SC, Jewell DP: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;i:1067-1070
12. Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;ii:1041-1048
13. Truelove SC, Witts LJ: Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954;ii:375-378
14. Kornbluth AA, Salomon P, Sacks HS, Mitty R, Janowitz HD: Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993; 16: 215-218
15. Hanauer SB: Inflammatory bowel disease. N Engl J Med 1996; 334: 841-848
16. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845
17. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR: Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001; 16: 1-9
18. Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T: Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003; 9: 307-321
19. Tung J, Loftus EV Jr, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ 3rd, Harmsen WS, Sandborn WJ, Faubion WA Jr: A population- based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006; 12: 1093-1100
20. Hiwatashi N, Yao T, Watanabe H, Hosoda S, Kobayashi K, Saito T, Terano A, Shimoyama T, Muto T: Long-term follow-up study of ulcerative colitis in Japan. J Gastroenterol 1995; 30(suppl 8):13-16
21. Langholz E, Munkholm P, Davidsen M, Binder V: Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11
22. Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J, Gendre JP: Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-279
23. Masson S, Nylander D, Mansfield JC: How important is onset of action in ulcerative colitis therapy? Drugs 2005; 65: 2069-2083
24. Jarnerot G, Rolny P, Sandberg-Gertzen H: Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-1013
25. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J: The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24: 319-330
26. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G: Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53
27. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CW, Jones FA: An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960; 1: 217-222
28. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M: Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-1197 (Pubitemid 23219711)
29. Bebb JR, Scott BB: How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004; 20: 143-149